Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Califf

Showing results (151-160 of 770) with videos related to

Pageof 77
Sort By:
JAMA|November 14, 2024
Why Evidence Generation Should Matter to Payers-ReplyAli B Abbasi, Lesley H Curtis, Robert M Califf
Journal of the American College of Cardiology|March 20, 2010
Biomarker bonanza?Robert M Califf, Svati H Shah, L Kristin Newby
The American Journal of Medicine|November 3, 2007
Clinical quality in non-ST-elevation acute coronary syndromesRobert M Califf, Rajendra H Mehta, Eric D Peterson
JAMA Network Open|January 16, 2019
Work and Cardiovascular Disease in ChinaHaider J Warraich, Tracy Y Wang, Robert M Califf
JAMA|November 20, 2015
Engaging Patients Across the Spectrum of Medical Product Development: View From the US Food and Drug AdministrationNina L Hunter, Kathryn M O'Callaghan, Robert M Califf
Nature Reviews. Drug Discovery|November 1, 2014
The Clinical Trials Transformation Initiative: innovation through collaborationPamela Tenaerts, Leanne Madre, Patrick Archdeacon, et al.
NPJ Digital Medicine|April 10, 2025
Is regulatory science ready for artificial intelligence?Thomas Hartung, Maurice Whelan, Weida Tong, et al.
Health Affairs (Project Hope)|September 13, 2006
How changes in drug-safety regulations affect the way drug and biotech companies invest in innovationShelby D Reed, Robert M Califf, Kevin A Schulman
American Heart Journal|December 9, 2008
Considerations of net present value in policy making regarding diagnostic and therapeutic technologiesRobert M Califf, Emma B Rasiel, Kevin A Schulman
The American Journal of Medicine|November 6, 2003
Translation of academic discovery into societal benefit: proposal for a balanced approach--part 1Jonathan S Stamler, Robert L Taber, Robert M Califf
Pageof 77

Showing results (151-160 of 770) with videos related to

Sort By:
Pageof 77
JAMA|November 14, 2024
Why Evidence Generation Should Matter to Payers-ReplyAli B Abbasi, Lesley H Curtis, Robert M Califf
Journal of the American College of Cardiology|March 20, 2010
Biomarker bonanza?Robert M Califf, Svati H Shah, L Kristin Newby
The American Journal of Medicine|November 3, 2007
Clinical quality in non-ST-elevation acute coronary syndromesRobert M Califf, Rajendra H Mehta, Eric D Peterson
JAMA Network Open|January 16, 2019
Work and Cardiovascular Disease in ChinaHaider J Warraich, Tracy Y Wang, Robert M Califf
JAMA|November 20, 2015
Engaging Patients Across the Spectrum of Medical Product Development: View From the US Food and Drug AdministrationNina L Hunter, Kathryn M O'Callaghan, Robert M Califf
Nature Reviews. Drug Discovery|November 1, 2014
The Clinical Trials Transformation Initiative: innovation through collaborationPamela Tenaerts, Leanne Madre, Patrick Archdeacon, et al.
NPJ Digital Medicine|April 10, 2025
Is regulatory science ready for artificial intelligence?Thomas Hartung, Maurice Whelan, Weida Tong, et al.
Health Affairs (Project Hope)|September 13, 2006
How changes in drug-safety regulations affect the way drug and biotech companies invest in innovationShelby D Reed, Robert M Califf, Kevin A Schulman
American Heart Journal|December 9, 2008
Considerations of net present value in policy making regarding diagnostic and therapeutic technologiesRobert M Califf, Emma B Rasiel, Kevin A Schulman
The American Journal of Medicine|November 6, 2003
Translation of academic discovery into societal benefit: proposal for a balanced approach--part 1Jonathan S Stamler, Robert L Taber, Robert M Califf
Pageof 77